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FARNESOID X RECEPTOR (FXR) is a member of the nuclear receptor superfamily. Highly expressed in the liver, small intestine, and kidney, FXR regulates the expression of genes involved in cholesterol, triglyceride, and glucose homeostasis (1, 2) . FXR regulates the transcription of target genes through the induction of the atypical nuclear receptor small heterodimer partner (SHP) (4, 10) . Despite lacking a DNA-binding domain, SHP is reported to repress transcription by binding to transcription factors of target genes (22) . An alternate mechanism of regulation by FXR occurs through the heterodimerization with the retinoic X receptor, which allows binding to specific response elements of target genes (21) .
Endogenous ligands of FXR are bile acids, major products of cholesterol metabolism (11, 18) . Bile acids are synthesized in the liver, stored in the gallbladder, and released into the small intestine, where they are crucial for the absorption of lipids and lipid-soluble nutrients (11) . Although the serum bile acid level is much lower than that found in the portal circulation, vasculature is known to be constantly exposed to a certain amount of bile acids. In healthy humans, the concentration of serum bile acids is known to fluctuate with diet (3, 13) . Furthermore, in liver diseases such as cirrhosis, the serum value of bile acids is dramatically raised, often reaching several hundred micromolars (13) .
Recent studies reported that FXR is also expressed both in vascular endothelial cells (5) and smooth muscle cells (1) , suggesting its physiological and/or pathological role in circulation. Indeed, several in vitro studies reported FXR agonism causes pathophysiological responses in vascular smooth muscle cells and endothelial cells, e.g., induction of apoptosis (1), upregulation of angiotensin type 2 receptor expression (24) in smooth muscle cells, suppression of endothelin-1 expression (5), and upregulation of endothelial nitric oxide (NO) synthase (eNOS) expression (8) . However, chronic effects of FXR stimulation on vascular tissue remain unknown.
Therefore, in the present study, we sought to assess the chronic effect of the FXR agonist GW4064 (12) on vascular contractility and endothelium-dependent relaxation (EDR) using an organ culture procedure. This procedure allows us to treat vascular tissue with test agents at constant concentrations under conditions similar to chronic in vivo FXR stimulation and examine its effects both on vascular contractile response and tissue morphology (16, 23) . Here we show that chronic stimulation of FXR impairs EDR, which is due to a decrease in the NO sensitivity of smooth muscle.
The arterial rings were then placed in 2 ml of DMEM in the presence or absence of GW4064 (0.1-10 M) or 6-ethyl chenodeoxycholic acid (6-ECDCA; 10 -100 M) supplemented with 1% penicillinstreptomycin. The rings were maintained at 37°C under an atmosphere of 95% air-5% CO 2 for 1 h to 7 days. The medium was changed every 2 days until the start of the experiments.
Measurement of muscle tension. Muscle tension was recorded isometrically as described previously (16) , with a force-displacement transducer (Orientic) connected to a strain amplifier (Yokogawa) under a resting tension of 10 mN. In the experiment examining the effect of GW4064 on vascular smooth muscle, the endothelium was removed by gently rubbing the intimal surface with forceps after the organ culture procedure. Data are shown as percentages of the relaxation of steady-state precontraction.
Cross-sectional hematoxylin-eosin staining. After the incubation, arterial rings were fixed with neutral buffered 10% formaldehyde for 2 days and embedded in paraffin. The 4-m-thick sections were stained with hematoxylin and eosin (HE). The slides were examined by light microscopy (Nikon Eclipse E800).
Whole mount immunostaining. Whole mount immunostaining was performed as described previously (15) . After the incubation, the arterial rings were fixed with 4% paraformaldehyde. The fixed rings were placed in 0.3% Triton X-100 in PBS for 30 min and 3% bovine serum albumin in PBS for 1 h. The arterial rings were then probed with anti-CD31 monoclonal antibody (Dako) at a 1:50 dilution. The images were captured using a confocal laser scanning microscope LSM510 imaging system (Carl Zeiss).
Measurement of cGMP content. After the incubation, the endothelium was removed by gently rubbing the intimal surface with a forceps. The arterial rings were placed in a normal physiological salt solution (PSS) and equilibrated for 2 h. The composition of PSS is the same as that used in muscle tension measurements. To facilitate cGMP measurement, the arterial rings were pretreated with IBMX (200 M) for 5 min to prevent the rapid turnover of accumulated cGMP by phosphodiesterases (PDEs). Subsequent to treatment with a test agent, the arterial rings were immediately frozen in liquid nitrogen, homogenized in 6% TCA, and centrifuged at 2,000 g for 15 min at 4°C. Supernatants were analyzed by an Amersham cGMP enzyme immunoassay biotrak system (GE Healthcare); the pellets were used to determine protein concentration by the Lowry method. cGMP concentration is expressed as femtomoles per microgram protein content.
Semiquantitative RT-PCR. After the incubation, total RNA was extracted from the arterial rings, and RT-PCR was performed as described previously (17) . The first strand of cDNA was synthesized using random 9 mer RT-primer and AMV Reverse Transcriptase XL at 30°C for 10 min, 55°C for 9 h, 99°C for 5 min, and 4°C for 5 min. PCR amplification using synthetic gene-specific primers for FXR, SHP, ␣1-and ␤1-subunit of soluble guanylyl cyclase (sGC), and GAPDH. PCR amplification was performed using Taq DNA polymerase (Ampli Taq Gold). The oligonucleotide primers were designed as follows: GAPDH, sense, GCATCCTGCACCACCAACTG, and antisense, GGTTTCTCCAGGCGGCATGTC; FXR, sense, CCCCAAGT-TCAACCACAGAT, and antisense, CCAGATGCTCTGTCTCCACA; SHP, sense, TCCCTCTTTCTGCTGGGTTT, and antisense, CAGGCTCA-GAAGGACTCCAG; sGC ␣1-subunit, sense, CAAGTTGTGCAAGC-CAAGAA, and antisense, ATCCAGCTCTCCACACTGTT; and sGC ␤1-subunit, sense, GGTTTGCCAGAACCTTGTATCCACC, and antisense, GAGTTTTCTGGGGACATGAGACACC. Denaturation was done at 95°C for 10 min, followed by amplification using a thermal cycler (Takara PCR Thermal Cycler MP; Takara Biomedicals).
For GAPDH and sGC ␣1-and ␤1-subunit, each cycle consisted of 0.6 min at 94°C, 1.5 min at 54°C, and 1.5 min at 72°C. For FXR, each cycle consisted of 0.6 min at 94°C, 1.5 min at 57°C, and 1.5 min at 72°C. For SHP, each cycle consisted of 0.6 min at 94°C, 1.5 min at 58°C, and 1.5 min at 72°C. PCR products after 27 to 39 cycles (3-cycle interval) were electrophoresed in a 2% agarose gel containing 0.1% ethidium bromide. The possibility of contaminating DNA was excluded by PCR with total RNA without a reverse transcription step. The densitometric intensity of the 308 bp of GAPDH at 30 cycles, the 245 bp for FXR at 36 cycles, the 197 bp for SHP at 36 cycles, the 156 bp for sGC ␣1-subunit at 33 cycles, and the 284 bp for sGC ␤1-subunit at 36 cycles was quantified using an image-processing program (ImageJ). The results are expressed as the ratios of the optical density of each PCR product to that of GAPDH.
Statistical analysis. The results of the experiments are expressed as means Ϯ SE. EC 50 values were determined from individual concentration response curves by nonlinear regression analysis and expressed as best-fit values and 95% confidence intervals. Statistical evaluation of the data was performed by the unpaired Student's t-test for comparisons between two groups and by one-way ANOVA followed by Dunnett's test for comparison between more than two groups. A value of P Ͻ 0.05 was taken as significant.
Chemicals. The chemicals used were as follows: DMEM, HBSS, IBMX, 8-bromoguanosine-cGMP (8-Br-cGMP), ionomycin (Sigma), endothelin-1, substance P (Peptide Institute), norepinephrine, sodium nitroprusside (Wako Pure Chemical), TRIzol reagent, ethidium bromide (Invitrogen), random 9 mer RT-primer (Takara Biomedical), AMV Reverse Transcriptase XL (Life Sciences), Ampli Taq Gold (Roche), and penicillin-streptomycin (Gibco). GW4064 was kindly donated by GlaxoSmithKline. 6-ECDCA was synthesized following a published protocol.
RESULTS

Induction of SHP mRNA expression induced by FXR stimulation.
In freshly isolated mesenteric arteries, FXR was constitutively expressed at mRNA level (intensity ratio to GAPDH, 0.53 Ϯ 0.03). The FXR mRNA level in the liver, which was higher than that in mesenteric arteries, was assessed as the positive control (intensity ratio to GAPDH, 1.36 Ϯ 0.11). It is well known that a FXR target gene, SHP, is induced after FXR activation. Therefore, we examined the expression level of SHP mRNA as an indicator of FXR activation by GW4064 in rabbit mesenteric arteries. As shown in Fig. 1 , SHP mRNA expression was significantly elevated 1 h after the administration of GW4064 (0.1-10 M) and then declined to the same level as that in nonstimulated arteries (3, 6 , and 24 h after administration; data not shown). Interestingly, the FXR mRNA expression level was also increased by treatment with GW4064 (1-10 M) for 1 h (Fig. 1) .
Chronic effects of FXR agonism on EDR. In a preliminary experiment, we confirmed that treatment with 0.1-10 M GW4064 (5 min for each dose) did not elicit contraction at a resting tension in freshly isolated mesenteric arteries. Treatment with 0.1-10 M GW4064 (5 min for each dose) after precontraction by 25 mM high K ϩ did not cause relaxation either (n ϭ 4 each; data not shown).
We next examined the chronic effect of FXR stimulation on vascular contractility using endothelium-denuded mesenteric arteries cultured for 7 days and found that chronic treatment with GW4064 (0.1-10 M) did not influence smooth muscle contractions induced by high K ϩ (15-65 mM) or norepinephrine (0.1-100 M). The absolute contractile force (millinewtons per milligrams wet weight) in the respective presence of 65 mM K ϩ and 100 M norepinephrine was as follows for the following agents: control, 53.4 Ϯ 6.7 and 67.2 Ϯ 9.7; 0.1 M GW4064, 43.9 Ϯ 4.1 and 59.2 Ϯ 5.9; 1 M GW4064, 55.7 Ϯ 8.1 and 67.2 Ϯ 9.7; and 10 M GW4064, 52.3 Ϯ 4.2 and 50.9 Ϯ 7.4 (n ϭ 6 each).
We next examined the chronic effect of FXR stimulation on EDR. A high K ϩ (25 mM) was chosen to induce precontraction because it elicited stable contractions of similar amplitudes in all the experiments (n ϭ 10 to 11). As shown in Fig. 2A , treatment with 1 M GW4064 for 7 days significantly impaired substance P (0.1-30 nM)-induced maximal EDR. In the arteries treated with higher concentrations of GW4064, the substance P-induced maximal EDR was inhibited on days 4 and 7. Figure 2B shows the effect of treatment with GW4064 (0.1-10 M) for 7 days on the dose-response curve for EDR induced by substance P. GW4064 (1-10 M) attenuated substance P-induced EDR in a dose-dependent manner (maximum relaxation, control, 84.4 Ϯ 4.2%, n ϭ 7; 1 M GW4064, 51.0 Ϯ 4.4%, n ϭ 4; and 10 M GW4064, 6.5 Ϯ 3.3%, n ϭ 6; P Ͻ 0.01). Figure 2C shows the effects of treatment with another FXR agonist, 6-ECDCA (10 -100 M), for 7 days on the relaxation induced by substance P. 6-ECDCA attenuated substance P- Fig. 2 . Effects of treatment with FXR agonist for 7 days on endothelium-dependent relaxation in endotheliumintact rabbit mesenteric arteries. A: time-dependent changes in maximum relaxation induced by substance P in mesenteric arteries cultured with or without GW4064 (0.1-10 M). B: concentration response curve for relaxation induced by substance P in arteries cultured with or without GW4064 (0.1-10 M) for 7 days. C: concentration response curve for relaxation induced by substance P in arteries cultured with or without 6-ethyl chenodeoxycholic acid (6-ECDCA; 10 -100 M) for 7 days. D: concentration response curve for relaxation induced by ionomycin in arteries cultured with or without GW4064 (0.1-10 M) for 7 days. Substance P (0.1-30 nM) or ionomycin (0.1 nM-1 M) was added cumulatively after 25 mM high K ϩ -induced contraction reached steady-state level. *Significantly different from the results in control arteries at P Ͻ 0.05; **significantly different from the results in control arteries at P Ͻ 0.01. In all of the arteries without endothelium, substance P was ineffective. The substance P-induced EDR in the cultured mesenteric arteries was eliminated by pretreatment with a NO synthase inhibitor, N G -monomethyl-L-arginine (300 M; 20 min before the addition of 25 mM K ϩ ; data not shown), suggesting that the EDR of mesenteric arteries is attributable mainly to NO production.
As shown in Fig. 2D , 1 M GW4064 (7 days) significantly attenuated and 10 M GW4064 (7 days) completely abolished Ca 2ϩ ionophore, ionomycin (0.1 nM-1 M)-induced EDR in 25 mM K ϩ -induced contraction (maximum relaxation, control, 80.5 Ϯ 6.7%; 1 M GW4064, 54.2 Ϯ 11.6%; and 10 M GW4064, Ϫ0.85 Ϯ 16.3%, n ϭ 5 each). In the 10 M GW4064-treated arteries, 0.3-1 M ionomycin caused contraction instead of relaxation. These phenomena may be due to a direct contractile effect of Ca 2ϩ ionophore on smooth muscle.
Chronic effects of GW4064 on the morphology of smooth muscle cells and endothelial cells.
To clarify the effects of GW4064 (0.1-10 M) on the morphology of the arteries, we performed HE cross staining in the arteries cultured for 7 days. As shown in Fig. 3A , treatment with GW4064 (0.1-10 M) for 7 days did not change the morphology of the arteries; the smooth muscle cells in the media layer were arranged in an ordinary manner and had typical spindle-shaped nuclei. Endothelial cells were attached tightly to the tunica interna. To further examine whether treatment with GW4064 (0.1-10 M) for 7 days causes morphological changes, such as excoriation or apoptosis-like change in endothelial cells, we performed whole mount en face CD31-immunostaining. As shown in Fig.  3B , endothelial cells were arranged like cobblestones in all the arteries, and no conspicuous change was found between GW4064 (0.1-10 M)-treated and control arteries.
Furthermore, we confirmed that chronic treatment with GW4064 (0.1-10 M, for 7 days) did not cause apoptotic cell death both in smooth muscle and endothelial layer using terminal deoxynucleotidyl transferase-mediated dUTP nickend labeling (TUNEL) assay (n ϭ 4 to 5; data not shown).
Chronic effects of GW4064 on NO sensitivity and cGMP production. In all the arteries without endothelium, sodium nitroprusside (SNP; 3 nM-100 M) caused vasorelaxation of the contractions elicited by 25 mM K ϩ in a dose-dependent manner, as shown in treatment for 5 min was also decreased by GW4064 in a dose-dependent manner (control, 326.8 Ϯ 34.1 fmol/g, n ϭ 4; 1 M GW4064, 199.1 Ϯ 33.6 fmol/g, n ϭ 5; and 10 M GW4064, 16.0 Ϯ 2.4 fmol/g, n ϭ 5). Stimulation with 100 M SNP increased the cGMP content in 1 M GW4064-treated arteries to 386.6 Ϯ 105.1 fmol/g (n ϭ 5), which was comparable with that of control arteries (327.8 Ϯ 106.2 fmol/ g, n ϭ 4). In 10 M GW4064-treated arteries, the 100 M SNP-induced cGMP elevations were still lower, but not significantly different, compared with those of control arteries (155.4 Ϯ 51.6 fmol/g, n ϭ 5). Figure 4C shows the effects of treatment with GW4064 (0.1-10 M) for 7 days on endothelium-denuded vascular relaxation induced by the cGMP analog 8-Br-cGMP (1-100 M). GW4064 (0.1-10 M) did not attenuate the 8-Br-cGMPinduced relaxation in muscle precontracted by 25 mM K ϩ (n ϭ 5 each).
We next investigated prostacyclin/cAMP-dependent relaxation in the arteries treated with GW4064. Of interest, as shown in Fig. 4D , the treatments with GW4064 (1-10 M) for 7 days accelerated iloprost-induced relaxation in a concentration-dependent manner (maximum relaxation, control, 29.5 Ϯ 6.6%, n ϭ 8; 1 M GW4064, 61.0 Ϯ 6.9%, n ϭ 7; and 10 M GW4064, 74.4 Ϯ 5.8%, n ϭ 7; P Ͻ 0.01).
Chronic effects of GW4064 on sGC mRNA expression. We next examined whether mRNA expression of sGC is altered by treatment with GW4064. sGC consists of two subunits, ␣-and ␤-subunit, and the most abundant isoform in vascular smooth muscle is the ␣ 1 /␤ 1 -heterodimer. As shown in Fig. 5 , the treatment with GW4064 (0.1-10 M, for 7 days) did not influence the mRNA expression level of the two subunits of sGC in endothelium-denuded arteries (n ϭ 7 to 8).
DISCUSSION
In this study, we showed that chronic stimulation of FXR impaired EDR in rabbit mesenteric arteries, which is due mainly to the decreased sensitivity of smooth muscle to NO. To our knowledge, this is the first demonstration of the chronic effects of FXR stimulation on vascular function.
As described in the INTRODUCTION, although FXR plays important roles in the expression of genes involved in cholesterol, triglyceride, and glucose homeostasis in the liver, recent reports suggest FXR is expressed in various organs and cell types inducing physiological and pathophysiological functions. In this study, we first confirmed that FXR mRNA was constitutively expressed in mesenteric arteries; however, its level was lower than that in the liver (Fig. 1) . This observation is consistent with previous reports showing FXR mRNA is expressed at lower levels in human umbilical vein endothelial cells (20) and human saphenous vein smooth muscle cells (1) compared with HepG2 cells (a human hepatocellular carcinoma cell line). In addition, we detected the induction of SHP mRNA expression stimulated by the FXR specific ligand GW4064. Since the expression of SHP is known to be induced upon FXR stimulation (1, 5) , it indicates GW4064 increases transcriptional regulatory activity of FXR under our experimental conditions. Another notable finding is that the expres- Fig. 4 . A: effects of treatment with GW4064 (0.1-10 M) for 7 days on relaxation induced by sodium nitroprusside (SNP) in endotheliumdenuded mesenteric arteries. SNP (3 nM-100 M) was added cumulatively after 25 mM high K ϩ -induced contraction reached steady-state level. B: effects of treatment with GW4064 (1-10 M) for 7 days on cGMP content in the endothelium-denuded mesenteric arteries. The graph shows the cGMP content in the absence or presence of 1 or 100 M SNP (5 min). C: effects of treatment with GW4064 (0.1-10 M) for 7 days on relaxation induced by 8-bromoguanosine-cGMP (8-Br-cGMP) in the endothelium-denuded mesenteric arteries. 8-Br-cGMP (1-100 M) was added cumulatively after 25 mM high K ϩ -induced contraction reached steady-state level. D: effects of treatment with GW4064 (0.1-10 M) for 7 days on relaxation induced by iloprost in the endothelium-denuded mesenteric arteries. Iloprost (0.1 nM-1 M) was added cumulatively after 25 mM high K ϩ -induced contraction reached steady-state level. *Significantly different from the results in control arteries at P Ͻ 0.05; **significantly different from the results in control arteries at P Ͻ 0.01. sion of FXR itself was also elevated by GW4064 in mesenteric arteries. This phenomenon was similar to that observed in in vitro studies on hepatocytes (7) and endothelial cells (5) . Taken together, these results suggest that GW4064 could activate the FXR signaling pathway in organ-cultured rabbit mesenteric arteries.
In the present study, we focused on the chronic effects of FXR stimulation on vascular function by using a vascular organ culture procedure. As we reported previously, the rabbit mesenteric arteries did not exhibit any functional or morphological changes after 7 days in organ culture (16, 23) , and thus this procedure makes it possible to assess the influence of chronic stimulation of FXR on vascular properties. The results indicated the chronic treatment with GW4064 did not influence vascular contractility stimulated by a high K ϩ , norepinephrine, and endothelin-1 in the endothelium-denuded arteries. In contrast, we found that GW4064 impaired substance P-induced EDR in a time-and dose-dependent manner in organ cultured arteries precontracted with a high concentration of K ϩ (Fig. 2,  A and B) . Consistent impairments were also obtained by another FXR agonist, 6-ECDCA (Fig. 2C) , suggesting chronic transcriptional activation of FXR could impair EDR in the vascular wall. When compared with GW4064, a relatively higher concentration of 6-ECDCA was required to hamper vasodilation. It has been reported that the strength of binding between 6-ECDCA and FXR is three times lower than that between GW4064 and FXR as assessed by a cell-free ligandsensing assay (19) . This difference in binding strength may be a potential reason for our current results. In mesenteric arteries with intact endothelium, GW4064 treatment impaired EDR, induced not only by receptor stimulation but also by the Ca 2ϩ ionophore ionomycin (Fig. 2D) . This observation let us rule out the possibility that GW4064 may influence the receptor-mediated Ca 2ϩ signal cascade in endothelial cells. In the next series of experiments, we examined mechanisms underlying FXR-mediated endothelial dysfunction. According to a previous report, bile acids (chenodeoxycholic and deoxycholic acids), as well as synthetic FXR ligands including GW4064, induced apoptosis in smooth muscle cells (1) . Therefore, we attempted to evaluate the possibility of GW4064-mediated FXR activation resulting in morphological changes in mesenteric arteries, possibly contributing to vascular dysfunction. However, in HE staining (Fig. 3A) , en face CD31 immunostaining (Fig. 3B) , and TUNEL assay, we did not detect any morphological changes caused by GW4064 in smooth muscle or endothelial cells, suggesting GW4064-mediated FXR activation does not induce any apoptotic effect on the vascular wall under our experimental conditions.
We next found that the chronic stimulation of FXR by GW4064 reduced the sensitivity of vascular smooth muscle to NO (Fig. 4A) . In smooth muscle cells, NO activates sGC, which in turn synthesizes cGMP. cGMP stimulates the cGMPdependent protein kinases, which inhibits Ca 2ϩ movements and Ca 2ϩ sensitization of contractile elements, resulting in smooth muscle relaxation (6, 14) . Although chronic FXR stimulation decreased SNP-induced cGMP production (Fig.  4B) , the stimulation did not influence smooth muscle response to 8-Br-cGMP (Fig. 4C) . Thus we concluded that the reduction in EDR observed in GW4064-treated arteries is mainly due to impairment of cGMP production in smooth muscle cells. Interestingly, GW4064 dose dependently increased cAMPmediated relaxation by iloprost (Fig. 4D ). There may be some compensatory systems following the impairment in NO/ cGMP-mediated relaxation.
In the present study, it remained unknown how chronic stimulation of FXR decreases cGMP content in smooth muscle cells. One possible mechanism is increased hydrolysis of cGMP by PDEs and the resulting accelerated decline of its effects. However, in this study, we analyzed cGMP production in the presence of the nonselective PDE inhibitor IBMX (200 M). Taken together, it suggests that chronic stimulation of FXR can induce dysfunction of sGC. This in turn inhibits cGMP production by NO, decreasing NO sensitivity of smooth muscle cells. As described earlier, FXR stimulation is reported to cause its physiological response via transcriptional regulations of target genes (2, 5, (7) (8) (9) 24 ). Therefore, it remained possible that chronic stimulation of FXR may suppress sGC gene expression, but GW4064 (0.1-10 M) did not change the ␣ 1 -and ␤ 1 -subunit mRNA level. This result leads to a speculation that FXR stimulation may modulate sGC activity at a posttranscriptional level including misdimerization of the ␣ 1 - and ␤ 1 -subunit, induction of endogenous inhibitors, and reduced interaction of substrates or cofactors.
Although we showed that chronic FXR stimulation impaired NO sensitivity in vascular smooth muscle layer, we did not examine its direct effect on NO productivity in endothelial layer, which may affect the EDR. Li et al. (8) recently reported that treatment with both GW4064 and one of the bile acids, chenodeoxycholic acid, upregulated eNOS mRNA expression and thus increased NO production in isolated endothelial cells. The discrepancy is that although our results suggest that the stimulation of FXR leads to hypertensive phenotype, their results suggest that it leads to hypotensive phenotype, which may be due to some factors including difference in the duration of FXR stimulation and experimental model (cultured vascular tissue or in vitro cultured cell).
Although the importance of FXR in pathophysiology or pathophysiology in vasculature remains unclear, it is well known that many patients with severe cirrhosis develop portal hypertension, and some candidates of liver transplantation have pulmonary hypertension. There is a possibility that chronic exposure of vascular tissue to high level of bile acids, and subsequent FXR activation, is involved in the progression of these circulatory disorders observed in patients with cirrhosis.
In conclusion, we showed here that chronic stimulation of FXR by its synthetic agonist GW4064 leads to the impairment of EDR in rabbit mesenteric arteries, which is mainly due to decreased NO sensitivity of smooth muscle. Although the physiological or pathophysiological importance of FXR-mediated impairment of EDR is not clearly understood at present, the fact that serum bile acid concentrations increase dramatically in liver disease indicates FXR may be involved in the pathophysiological processes of these diseases and their complications.
